

Technical Information Report

ANSI/AAMI/ ISO TIR13004: 2013/(R)2016

Sterilization of health care
products—Radiation—
Substantiation of a selected
sterilization dose: Method
 VD_{max}^{SD}

Sterilization of health care products—Radiation— Substantiation of a selected sterilization dose: Method $VD_{\max}^{SD}$

Approved 3 September 2013 by
AAMI

Registered 4 October 2013 and reaffirmed 22 August 2016 by
American National Standards Institute

Abstract: This Technical Specification describes a method for substantiating a selected sterilization dose of 17.5, 20, 22.5, 27.5, 30, 32.5 or 35 kGy that achieves a sterility assurance level (SAL) of 10^{-6} or less for radiation sterilization of health care products. This Technical Specification also specifies a method of sterilization dose audit used to demonstrate the continued effectiveness of the substantiated sterilization dose.

Keywords: ISO 11137-2, Method $VD_{\max}^{25}$, Method $VD_{\max}^{15}$

Published by

AAMI
4301 N. Fairfax Drive, Suite 301
Arlington, VA 22203-1633
www.aami.org

© 2013 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of ISO, ANSI, and AAMI. No part of this publication may be reproduced or distributed in any form, including an electronic retrieval system, without the prior written permission of AAMI. All requests pertaining to this document should be submitted to AAMI. It is illegal under federal law (17 U.S.C. § 101, et seq.) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, complete the reprint request form at www.aami.org or contact AAMI at 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633. Phone: +1-703-525-4890; Fax: +1-703-276-0793.

Printed in the United States of America

ISBN 1-57020-504-3

AAMI Technical Information Report

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that, although both standards and TIRs are periodically reviewed, a standard must be acted on—reaffirmed, revised, or withdrawn—and the action formally approved usually every five years but at least every 10 years. For a TIR, AAMI consults with a technical committee about five years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful, the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

CAUTION NOTICE: This AAMI TIR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are voluntary, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633.

ANSI Technical Report

This AAMI TIR has been registered by the American National Standards Institute as an ANSI Technical Report.

Publication of this ANSI Technical Report has been approved by the accredited standards developer (AAMI). This document is registered as a Technical Report series of publications according to the Procedures for the Registration of Technical Reports with ANSI. This document is not an American National Standard and the material contained herein is not normative in nature.

Comments on the content of this document should be sent to AAMI, Attn: Standards Department, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633.

Contents

Page

Glossary of equivalent standards	vii
Committee representation.....	viii
Background of AAMI adoption of ISO TS 13004:2013.....	xi
Foreword	xii
Introduction	xiii
1 Scope.....	1
1.1 Inclusions	1
1.2 Exclusions	1
1.3 Application.....	1
2 Normative references	1
3 Terms and definitions.....	2
4 Definition and maintenance of product families for sterilization dose substantiation and sterilization dose auditing	6
4.1 General.....	6
4.2 Defining product families	6
4.3 Designation of product to represent a product family.....	7
4.3.1 Product to represent a product family.....	7
4.3.2 Master product	8
4.3.3 Equivalent product.....	8
4.3.4 Simulated product.....	8
4.4 Maintaining product families	9
4.4.1 Periodic review.....	9
4.4.2 Modification to product and/or manufacturing process	9
4.4.3 Records.....	9
4.5 Consequence of failure of sterilization dose substantiation or sterilization dose audit.....	9
5 Selection and testing of product for substantiating and auditing a selected sterilization dose.....	10
5.1 Nature of product	10
5.2 Sample item portion (SIP)	11
5.3 Manner of sampling	12
5.4 Microbiological testing	12
5.5 Irradiation.....	13
6 Method VD_{max}^{SD} — Substantiation of a selected sterilization dose of 17.5, 20, 22.5, 27.5, 30, 32.5, or 35 kGy.....	13
6.1 Rationale	13
6.2 Procedure for Method VD_{max}^{SD} for multiple production batches	14
6.2.1 General	14
6.2.2 Stage 1: Obtain samples of product	14
6.2.3 Stage 2: Determine average bioburden	14
6.2.4 Stage 3: Obtain the selected sterilization dose	15
6.2.5 Stage 4: Obtain VD_{max}^{SD}	16
6.2.6 Stage 5: Perform verification dose experiment	17
6.2.7 Stage 6: Interpretation of results.....	18
6.2.8 Confirmatory verification dose experiment.....	18

6.3	Procedure for Method VD_{max}^{SD} for a single production batch	20
6.3.1	Rationale	20
6.3.2	General	20
6.3.3	Stage 1: Obtain samples of product	20
6.3.4	Stage 2: Determine average bioburden	20
6.3.5	Stage 3: Obtain the selected sterilization dose	21
6.3.6	Stage 4: Obtain VD_{max}^{SD}	21
6.3.7	Stage 5: Perform verification dose experiment	22
6.3.8	Stage 6: Interpretation of results.....	22
6.3.9	Confirmatory verification dose experiment.....	23
7	Maintaining process effectiveness	24
7.1	General	24
7.2	Determination of bioburden	25
7.2.1	Background to frequency of determination	25
7.2.2	Frequency of determination specific to Method VD_{max}^{SD}	25
7.3	Sterilization dose audit.....	25
7.3.1	Frequency	25
7.3.2	Outcome.....	25
7.3.3	Procedure for auditing a sterilization dose substantiated using Method VD_{max}^{SD}	26
7.3.4	Failure of a sterilization dose audit.....	30
8	Tables of values for SIP equal to 1.0 VD_{max}^{SD} , SIP dose reduction factor and augmentation dose corresponding to applicable values of average bioburden for selected sterilization doses of 17.5, 20, 22.5, 27.5, 30, 32.5 and 35 kGy	30
9	Worked examples.....	64
9.1	Substantiation of a selected sterilization dose of 17.5 kGy (SIP less than 1.0)	64
9.2	Substantiation of a selected sterilization dose of 30 kGy (SIP equal to 1.0)	66
9.3	Sterilization dose audit for a sterilization dose substantiated using Method $VD_{max}^{22.5}$, the findings from which necessitated augmentation of the sterilization dose	67
	Bibliography	69
	Tables	
	Table 1 — Nature of product items for sterilization dose substantiation and for sterilization dose auditing	10
	Table 2 — Examples for calculation of SIP	11
	Table 3 — Upper limit of average bioburden for selection of a given sterilization dose	16
	Table 4 — Table in Clause 8 corresponding to the selected sterilization dose	16
	Table 5 — 17.5 kGy selected sterilization dose for which the upper limit of average bioburden is 9.0	31
	Table 6 — 20 kGy selected sterilization dose for which the upper limit of average bioburden is 45	32
	Table 7 — 22,5 kGy selected sterilization dose for which the upper limit of average bioburden is 220	35
	Table 8 — 27.5 kGy selected sterilization dose for which the upper limit of average bioburden is 5,000	39
	Table 9 — 30 kGy selected sterilization dose for which the upper limit of average bioburden is 23,000	44

Table 10 — 32.5 kGy selected sterilization dose for which the upper limit of average bioburden is 100,000	50
Table 11 — 35 kGy selected sterilization dose for which the upper limit of average bioburden is 440,000	57
Table 12 — Method $VD_{max}^{17.5}$ substantiation (SIP less than 1.0)	65
Table 13 — Method VD_{max}^{30} substantiation (SIP equal to 1.0)	66
Table 14 — Sterilization dose audit following which augmentation of the sterilization dose was required (selected sterilization dose substantiated using Method $VD_{max}^{22.5}$)	67

Glossary of equivalent standards

International Standards adopted in the United States may include normative references to other International Standards. AAMI maintains a current list of each International Standard that has been adopted by AAMI (and ANSI). Available on the AAMI website at the address below, this list gives the corresponding U.S. designation and level of equivalency to the International Standard.

www.aami.org/standards/glossary.pdf



Committee representation

Association for the Advancement of Medical Instrumentation

Radiation Sterilization Working Group

The adoption of ISO Technical Specification (TS) 13004, as an AAMI Technical Information Report was initiated by the AAMI Radiation Sterilization Working Group, which also functions as the U.S. Technical Advisory Group to the relevant work in the International Organization for Standardization (ISO). U.S. representatives from the AAMI Radiation Sterilization Working Group (U.S. Sub-TAG for ISO/TC 198/WG 2, Radiation Sterilization) played an active role in developing the ISO Technical Specification.

At the time this document was published, the **AAMI Sterilization Standards Committee** had the following members:

Cochairs Victoria M. Hitchins, PhD, FDA/CDRH
Michael H. Scholla, Dupont Protection Technologies

Members Janet Prust, 3M Healthcare
Byron Lambert, Abbott Laboratories
Jeff Martin, Alcon Laboratories Inc.
Ramona Conner, Association of Perioperative Registered Nurses
Patrick McCormick, Bausch & Lomb Inc.
Mark Seybold, Baxter Healthcare Corporation
Lisa Macdonald, Becton Dickinson & Company
Christopher Anderson, Boston Scientific Corporation
Trabue Bryans, BryKor LLC
Rey Lopez, Cardinal Health (MP&S)
Phil Cogdill, Covidien
Kim Darnell, CR Bard
Mark Smith, Getinge USA
Deborah Havlik, Hospira Worldwide Inc.
Sue Klacik, IAHCSMM
Joyce Hansen, Johnson & Johnson
Lisa Foster, Medpoint LLC
Nancy Rakiewicz, Moog Medical Devices
Joel Gorski, NAMSA
Martell Winters, Nelson Laboratories Inc.
Andrew Sharavara, Propper Manufacturing Co Inc.
Jackie Daley, Sinai Hospital of Baltimore
Nancy Chobin, St Barnabas Healthcare System
Bill Young, Sterigenics International
Doug Harbrecht, Sterility Assurance LLC
Gerald McDonnell, Steris Corporation
Colleen Landers, Timmins & District Hospital

Alternates Craig Wallace, 3M Healthcare
David McGoldrick, Abbott Laboratories
Jim Kaiser, Bausch & Lomb Inc.
Mike Sadowski, Baxter Healthcare Corporation
Glenn Calvert, Becton Dickinson & Company
Ralph Makinen, Boston Scientific Corporation
Dave Dion, Cardinal Health (MP&S)
Lloyd Brown, Covidien
Mary Mayo, CR Bard
Karen Polkinghorne, Dupont Protection Technologies
Natalie Lind, IAHCSMM
Tom Frazar, Johnson & Johnson
Patrick Polito, Moog Medical Devices
Shaundrea Rechsteiner, NAMSA

Jerry Nelson, Nelson Laboratories Inc.
Martha Kadas, Sterigenics International
Pete Burke, Steris Corporation
Gordon Ely, WuXi AppTec Inc.

NOTE--Participation by federal agency representatives in the development of this document does not constitute endorsement by the federal government or any of its agencies.

At the time this document was published, the **Radiation Sterilization Working Group** had the following members:

<i>Cochairs</i>	Trabue Bryans, BryKor LLC Lisa Foster, Medpoint LLC
<i>Members</i>	Simon Bogdanský, Allo Source Curt Bogue, Cook Inc. Anne Booth, Booth Scientific Inc. Harry Bushar, Bushar, Harry - 1166 Glenn Calvert, Becton Dickinson & Company Rebecca Campbell, Sterigenics International Vin Caputo, WL Gore & Associates Inc. Denise Cleghorn, Boston Scientific Corporation Gary Cranston, Consulting & Technical Services/PCS Emily Craven, Nordion Inc. Greg Crego, Moog Medical Devices Elaine Daniell, CR Bard Douglas Davie, Sterilization Validation Services Staci DeMoss, NAMSA Darci Diage, Direct Flow Medical Inc. April Doering, St Jude Medical Inc. William FitzGerald, FitzGerald & Associates Ltd Sarah Gagnon, Microtest Laboratories Inc. Chris Haas, Covidien Joyce Hansen, Johnson & Johnson Thomas Hansen, Terumo Americas Corporate Doug Harbrecht, Sterility Assurance LLC Deborah Havlik, Hospira Worldwide Inc. Betty Howard, Steris Corporation Brent Huberty, Medtronic Inc. WHQ Campus Jim Kaiser, Bausch & Lomb Inc. David King, Tandem Diabetes Care Inc. Carolyn Kinsley, LexaMed Ltd John Kowalski, MicroGAMMA LLC Byron Lambert, Abbott Laboratories Rey Lopez, Cardinal Health (MP&S) Ronald Lulich, 3M Healthcare Jeff Martin, Alcon Laboratories Inc. Joseph Mello, Ethide Laboratories Inc. Rusty Mills, GE Healthcare Larry Nichols, Nutek Corporation Gerry O'Dell, Gerry O'Dell Consulting Dave Parente, Ecolab Michelle Peterson, Stryker Instruments Division Rudy Pina, Dynatec Scientific Labs Inc. Manneu Saavedra, Kimberly-Clark Corporation Jon Seulean, Terumo BCT Harry Shaffer, Sterilization Consulting Services Ian Shorr, CareFusion Sopheak Srun, Quality Tech Services Inc. Fenil Sutaria, Medline Industries Inc.

Bud Weisman, Fresenius Medical Care Renal Therapies Group
Pat Weixel, FDA/CDRH
John Williams, Baxter Healthcare Corporation
Martell Winters, Nelson Laboratories Inc.

Alternates

Marjean Boyter, Fresenius Medical Care Renal Therapies Group
Claudia Camp, Stryker Instruments Division
David Cardin, Zimmer Inc.
Jessica Desmond, Microtest Laboratories Inc.
John DiCaro, Covidien
Dave Dion, Cardinal Health (MP&S)
Brian Drumheller, CR Bard
Niki Fidopiastis, Sterigenics International
Shelley Green, WuXi AppTec Inc.
Chris Johnson, Steris Corporation
Chris Kobus, GE Healthcare
Ezra Koski, Terumo BCT
Maggie Ladd, Kimberly-Clark Corporation
Antonio Lopez-Feliciano, CareFusion
Jody Markling, St Jude Medical Inc.
Patrick McCormick, Bausch & Lomb Inc.
Alan Montgomery, Becton Dickinson & Company
Kimberly Patton, Becton Dickinson & Company
Michelle Pierce, NAMSA
Nancy Rakiewicz, Moog Medical Devices
Robert Reich, LexaMed Ltd
Reginald Roberts, Medline Industries Inc.
Matt Roybal, Johnson & Johnson
Jody Rupert, WL Gore & Associates Inc.
Mark Seybold, Baxter Healthcare Corporation
Michael Sprague, Ethide Laboratories Inc.
Wendy Wangsgard, Nelson Laboratories Inc.
Cas Woss, FitzGerald & Associates Ltd

NOTE—Participation by federal agency representatives in the development of this standard does not constitute endorsement by the federal government or any of its agencies.

Background of ANSI/AAMI adoption of ISO/TS 13004:2013

As indicated, the parent ISO Radiation Sterilization standard, ISO 11137-2, *Sterilization of health care products -- Radiation -- Part 2: Establishing the sterilization dose*, includes Method VD_{max}^{25} and Method VD_{max}^{15} . Following publication of peer reviewed literature demonstrating the appropriateness of extending the method to 35 kGy, the TS was developed including Method VD_{max}^{SD} at 17.5, 20, 22.5, 27.5, 30, 32.5 and 35 kGy.

Method VD_{max}^{25} and Method VD_{max}^{15} are not included in ISO/TS 13004 to avoid repetition and any possible conflict with ISO 11137-2. The TS was developed in parallel with but slightly after ISO 11137-2:2012; hence the documents are harmonized to a large degree. All the revisions to Method VD_{max}^{25} and Method VD_{max}^{15} incorporated into ISO 11137-2:2012 are also incorporated into ISO/TS 13004.

AAMI TIR33:2005, *Sterilization of health care products — Radiation — Substantiation of a sterilization dose: Method VD_{max} was foundational for the development of ISO/TS13004*. TIR33:2005 includes the doses of the TS and also includes 25 and 15 kGy. However, it has not benefited from the revisions to Method VD_{max}^{SD} provided in ISO 11137-2:2013, 3rd Edition and in the development of ISO/TS13004. For example, there are multiple clauses in Method VD_{max}^{SD} with parallel but slightly differing requirements, e.g., multiple batch and single batch; original and confirmatory verification dose experiments; and dose auditing procedures. In the ISO revision process, these parallel sections were harmonized to provide improved clarity, readability and precision of terminology. Of particular note is the harmonization of parallel sections specifying dose tolerances and interpretation of results for verification dose experiments and dose audits. A revision of TIR33 is currently planned by ST/WG2.

AAMI and ANSI procedures require that standards be reviewed and, if necessary, revised every five years to reflect technological advances that may have occurred since publication.

AAMI (and ANSI) have adopted other ISO standards. See the Glossary of Equivalent Standards for a list of ISO standards adopted by AAMI that gives the corresponding U.S. designation and the level of equivalency with the ISO standard.

As used within the context of this document, “shall” indicates requirements strictly to be followed to conform to the standard. “Should” indicates that among several possibilities, one is recommended as particularly suitable, without mentioning or excluding others, or that a certain course of action is preferred but not necessarily required, or that (in the negative form) a certain possibility or course of action should be avoided but is not prohibited. “May” is used to indicate that a course of action is permissible within the limits of the standard. “Can” is used as a statement of possibility and capability. Finally, “must” is used only to describe “unavoidable” situations, including those mandated by government regulation.

The concepts incorporated in this document should not be considered inflexible or static. This standard, like any other, must be reviewed and updated periodically to assimilate progressive technological developments. To remain relevant, it must be modified as technological advances are made and as new data come to light.

Suggestions for improving this document are invited. Comments and suggested revisions should be sent to Standards Department, AAMI, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633.

NOTE—Beginning with the ISO foreword on page xii, this AAMI TIR is identical to ISO/TS 13004:2013.

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

In other circumstances, particularly when there is an urgent market requirement for such documents, a technical committee may decide to publish other types of normative document:

- an ISO Publicly Available Specification (ISO/PAS) represents an agreement between technical experts in an ISO working group and is accepted for publication if it is approved by more than 50 % of the members of the parent committee casting a vote;
- an ISO Technical Specification (ISO/TS) represents an agreement between the members of a technical committee and is accepted for publication if it is approved by 2/3 of the members of the committee casting a vote.

An ISO/PAS or ISO/TS is reviewed after three years in order to decide whether it will be confirmed for a further three years, revised to become an International Standard, or withdrawn. If the ISO/PAS or ISO/TS is confirmed, it is reviewed again after a further three years, at which time it must either be transformed into an International Standard or be withdrawn.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO/TS 13004 was prepared by Technical Committee ISO/TC 198, Sterilization of health care products.

Introduction

This Technical Specification is intended to be used in conjunction with ISO 11137-1, *Sterilization of health care products—Radiation—Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*. One of the activities encompassed within process definition in ISO 11137-1 is the option to select and substantiate a sterilization dose to be applied to health care products.

ISO 11137-2 includes Method VD_{max} for the substantiation of 25 kGy as a sterilization dose (termed Method VD_{max}^{25}) for product with an average bioburden less than or equal to 1,000 and Method VD_{max}^{15} for the substantiation of 15 kGy as a sterilization dose for product with an average bioburden less than or equal to 1.5.

This Technical Specification extends the methods of selection and substantiation of a sterilization dose specified in ISO 11137-2. It provides a methodology for the substantiation of selected sterilization doses of 17.5, 20, 22.5, 27.5, 30, 32.5 and 35 kGy, each of which is valid only for a specified upper limit of average bioburden.

NOTE Selected sterilization doses of 25 kGy and 15 kGy are not included in this Technical Specification. The seven methods in this Technical Specification follow the same technical steps as the methods given in ISO 11137-2 for selection and substantiation of sterilization doses of 25 kGy and 15 kGy. However, the descriptive text in this Technical Specification has been modified to better communicate the methods, and hence the text occasionally differs from that in ISO 11137-2.

The method described in this Technical Specification is for substantiation of a selected sterilization dose to achieve a sterility assurance level (SAL) of 10^{-6} or less at that dose, (e.g., Method VD_{max}^{20} for a selected sterilization dose of 20 kGy). The application of the method is not limited by production batch size or production frequency, and the number of product items irradiated in the verification dose experiment remains constant. The method is founded on and embodies the following three principles:

- existence of a direct link between the outcome of the verification dose experiment and the attainment of an SAL of 10^{-6} at the selected sterilization dose;
- possession of a level of conservativeness at least equal to that of the standard distribution of resistances (SDR);
- for a given bioburden, use of a maximal verification dose (VD_{max}) corresponding to substantiation of a selected sterilization dose.

This approach to sterilization dose substantiation was first outlined by Kowalski and Tallentire^[6] and, from subsequent evaluations involving computational techniques (Kowalski, Aoshuang and Tallentire^[7]) and field evaluations (Kowalski et al^[8]), it was concluded that the method is soundly based. An overview of the method and aspects of putting it into practice are provided in Kowalski and Tallentire.^{[9][10]} Application of the Method VD_{max} approach to doses other than 25 kGy is discussed in Kowalski and Tallentire.^{[11][12]}

The method described here and designated Method VD_{max}^{SD} procedurally comprises elements that closely parallel those of dose setting Method 1 described in ISO 11137-2. One key area of difference is the number of product items used in the verification dose experiment. In the

computer evaluations referred to above, changing the verification SAL value had little effect on the substantiation outcome and this finding led to a sample size of 10 product items being chosen for subsequent field evaluations and, ultimately, for inclusion in this document.

Manufacturers of health care products who intend to use this specification are reminded that the requirements contained in ISO 11137 apply to the manufacture and control of production batches destined for radiation sterilization. In particular, one requirement states that products have to be manufactured in circumstances such that the bioburden is controlled. Compliance with the requirements for controlling the quality of raw materials; the manufacturing environment; the health, hygiene, and attire of personnel; and for establishing the basic properties of packaging material is essential.

Sterilization of health care products—Radiation— Substantiation of a selected sterilization dose: Method $VD_{\max}^{SD}$

1 Scope

1.1 Inclusions

This Technical Specification describes a method for substantiating a selected sterilization dose of 17.5, 20, 22.5, 27.5, 30, 32.5 or 35 kGy that achieves a sterility assurance level (SAL) of 10^{-6} or less for radiation sterilization of health care products. This Technical Specification also specifies a method of sterilization dose audit used to demonstrate the continued effectiveness of the substantiated sterilization dose.

NOTE Selection and substantiation of the sterilization dose is used to meet the requirements for establishing the sterilization dose within process definition in ISO 11137-1.

1.2 Exclusions

This method is for the substantiation of a selected sterilization dose of 17.5, 20, 22.5, 27.5, 30, 32.5, or 35 kGy only and is not used to substantiate other sterilization doses. The method is not used for the substantiation of a selected sterilization dose if the average bioburden of the entire product item exceeds the limit specified for the selected sterilization dose (see Table 3).

NOTE The methods for substantiation of selected sterilization doses of 25 kGy and 15 kGy are not included in this Technical Specification; they are described in ISO 11137-2.

1.3 Application

If the decision is made to use this method of sterilization dose establishment, the method is to be followed according to the requirements (shall) and guidance (should) stipulated herein.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 11137-1:2006, *Sterilization of health care products — Radiation — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*

ISO 11737-1:2006, *Sterilization of medical devices —Microbiological methods —Part 1: Determination of a population of microorganisms on products*

ISO 11737-2:2009, *Sterilization of medical devices —Microbiological methods —Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process*

3 Terms and definitions

For the purposes of this document, the following abbreviations, terms and definitions apply.

3.1

batch

defined quantity of product, intended or purported to be uniform in character and quality, that has been produced during a defined cycle of manufacture

[SOURCE: ISO/TS 11139:2006, 2.1]

3.2

bioburden

population of viable microorganisms on or in product and/or sterile barrier system

[SOURCE: ISO/TS 11139:2006, 2.2]

3.3

correction

action to eliminate a detected nonconformity

NOTE A correction can be made in conjunction with corrective action (3.4).

[SOURCE: ISO 9000:2005, 3.6.6, modified]

3.4

corrective action

action to eliminate the cause of a detected nonconformity or other undesirable situation

NOTE 1 There can be more than one cause for a nonconformity.

NOTE 2 Corrective action is taken to prevent recurrence, whereas preventive action is taken to prevent occurrence.

NOTE 3 There is a distinction between correction and corrective action.

[SOURCE: ISO 9000:2005, 3.6.5]

3.5

dose

absorbed dose

quantity of ionizing radiation energy imparted per unit mass of specified material

NOTE 1 The unit of absorbed dose is the gray (Gy), where 1 Gy is equivalent to the absorption of 1 J/kg.

NOTE 2 For the purposes of this document, the term dose is used to mean absorbed dose.

[SOURCE: ISO 11137-1:2006, 3.1, modified]

3.6

dose mapping

measurement of dose distribution and variability in material irradiated under defined conditions

[SOURCE: ISO 11137-1:2006, 3.10]

3.7

false positive

test result interpreted as growth arising from product, or portion thereof, tested when either growth resulted from extraneous microbial contamination or turbidity occurred from interaction between the product, or portion thereof, and the test medium

[SOURCE: ISO 11137-2:2012, 3.1.3]

3.8

health care product(s)

medical device(s), including *in vitro* diagnostic medical device(s), or medicinal product(s), including biopharmaceutical(s)

[SOURCE: ISO/TS 11139:2006, 2.20]

3.9

medical device

instrument, apparatus, implement, machine, appliance, implant, *in vitro* reagent or calibrator, software, material, or other related article intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the specific purpose(s) of:

- diagnosis, prevention, monitoring, treatment, or alleviation of disease;
- diagnosis, monitoring, treatment, alleviation of or compensation for an injury;
- investigation, replacement, modification, or support of the anatomy or of a physiological process;
- supporting or sustaining life;
- control of conception;
- disinfection of medical devices;
- providing information for medical purposes by means of *in vitro* examination of specimens derived from the human body;

and which does not achieve its primary intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means

NOTE This definition from ISO 13485 has been developed by the Global Harmonization Task Force (GHTF 2002).

[SOURCE: ISO 13485:2003, 3.7, modified]

3.10

Method VD_{max}

procedure for sterilization dose substantiation that uses the maximal verification dose for a given bioburden, consistent with the attainment of a SAL of 10^{-6} at a selected sterilization dose

NOTE The substantiation method is generally referred to as Method VD_{max}^{SD} , where SD takes the value of the selected sterilization dose.

3.11

microorganism

entity of microscopic size, encompassing bacteria, fungi, protozoa, and viruses

NOTE A specific standard might not require demonstration of the effectiveness of the sterilization process in inactivating all types of microorganisms, identified in the definition above, for validation and/or routine control of the sterilization process.

[SOURCE: ISO/TS 11139:2006, 2.26]

3.12

packaging system

combination of the sterile barrier system and protective packaging

[SOURCE: ISO/TS 11139:2006, 2.28]

3.13

positive test of sterility

test result for which there is detectable microbial growth from product, or portion thereof, subjected to a test of sterility

[SOURCE: ISO 11137-2:2012, 3.1.8]

3.14

product

result of a process

NOTE For the purposes of sterilization standards, product is tangible and can be raw material(s), intermediate(s), sub-assembly(ies), or health care product(s)

[SOURCE: ISO 9000:2005, 3.4.2, modified]

3.15

sample item portion

SIP

defined portion of a health care product that is tested

[SOURCE: ISO 11137-2:2012, 3.1.9]

3.16

sterile barrier system

minimum package that prevents ingress of microorganisms and allows aseptic presentation of product at the point of use

[SOURCE: ISO/TS 11139:2006, 2.44]

3.17

sterility

state of being free from viable microorganisms

NOTE In practice, no such absolute statement regarding the absence of microorganisms can be proven [see **sterilization** (3.19)].

[SOURCE: ISO/TS 11139:2006, 2.45]

3.18

sterility assurance level

SAL

probability of a single viable microorganism occurring on an item after sterilization

NOTE The term SAL takes a quantitative value, generally 10^{-6} or 10^{-3} . When applying this quantitative value to assurance of sterility, an SAL of 10^{-6} has a lower value but provides a greater assurance of sterility than an SAL of 10^{-3} .

[SOURCE: ISO/TS 11139:2006, 2.46]

3.19

sterilization

validated process used to render product free from viable microorganisms

NOTE In a sterilization process, the nature of microbial inactivation is exponential and thus the survival of a microorganism on an individual item can be expressed in terms of probability. While this probability can be reduced to a very low number, it can never be reduced to zero [see **sterility assurance level** (3.18)].

[SOURCE: ISO/TS 11139:2006, 2.47]

3.20

sterilization dose

SD

dose selected to achieve the specified requirements for sterility

[SOURCE: ISO 11137-1:2006, 3.40, modified]

3.21

sterilization dose audit

exercise undertaken to confirm the appropriateness of an established sterilization dose

[SOURCE: ISO 11137-2:2012, 3.2.12]

3.22

test of sterility

technical operation performed as part of development, validation, or requalification to determine the presence or absence of viable microorganisms on product or portion thereof

[SOURCE: ISO/TS 11139:2006, 2.54]

3.23

verification dose

dose predicted to give a predetermined SAL greater than or equal to 10^{-2} used in establishing the sterilization dose

NOTE For the purpose of this Technical Specification, this predetermined SAL is 10^{-1} .

3.24

$VD_{\max}^{SD}$

maximal verification dose for a particular selected sterilization dose (SD) obtained in using Method $VD_{\max}^{SD}$

4 Definition and maintenance of product families for sterilization dose substantiation and sterilization dose auditing

4.1 General

The establishment of a sterilization dose, for which sterilization dose selection and substantiation can be undertaken, and the carrying out of sterilization dose audits are activities that are part of process definition and maintaining process effectiveness (see ISO 11137-1). For these activities, product may be grouped into families; definition of product families is based principally on the numbers and types of microorganisms on or in product (the bioburden), the type being indicative of the microorganism's resistance to radiation (see ISO 11737-1). Variables such as density and product configuration within its packaging system are not considered in the establishment of these product families, because they are not factors that influence bioburden.

In using product families for establishing the sterilization dose and for carrying out sterilization dose audits, it is important to be aware of the reduction in the ability to detect an inadvertent change within the manufacturing process that influences the effectiveness of sterilization. Furthermore, with the use of a single product to represent the product family, changes that occur in other members of the product family might not be detected. The effect of a reduction on ability to detect changes in other members of the product family should be evaluated and a plan for maintaining product families developed and implemented before proceeding.

4.2 Defining product families

4.2.1 The criteria for defining a product family shall be documented. Product shall be assessed against these criteria and the similarities between potential product family members considered. Consideration shall include all product-related variables that affect bioburden, including, but not limited to:

- a) nature and sources of raw materials, including the effect, if any, of raw materials that might be sourced from more than one location;
- b) components;
- c) product design and size;
- d) manufacturing processes;
- e) manufacturing equipment;
- f) manufacturing environment;
- g) manufacturing location.

The outcome of the assessment and considerations shall be recorded (see 4.1.2 of ISO 11137-1:2006).

4.2.2 Product shall only be included in a product family if it is demonstrated that the product-related variables (see 4.2.1) are similar and under control.

4.2.3 To include product within a product family, it shall be demonstrated that bioburden comprises similar numbers and types of microorganisms.

4.2.4 Inclusion of product from more than one manufacturing location in a product family shall be specifically justified and recorded (see 4.1.2 of ISO 11137-1:2006). Consideration shall be given to the effect on bioburden of:

- a) geographic and/or climatic differences between locations;
- b) any differences in the control of the manufacturing processes or environment;
- c) sources of raw materials and processing adjuvants (e.g. water).

4.3 Designation of product to represent a product family

4.3.1 Product to represent a product family

4.3.1.1 The number and types of microorganisms on or in product shall be used as the basis for selecting product to represent a product family.

4.3.1.2 A product family shall be represented by:

- a) a master product (see 4.3.2), or
- b) an equivalent product (see 4.3.3), or
- c) a simulated product (see 4.3.4).

4.3.1.3 A formal, documented assessment shall be undertaken to decide which of the three potential representative products in 4.3.1.2 is appropriate. In this assessment, consideration shall be given to the following:

- a) number of microorganisms comprising the bioburden;
- b) types of microorganisms comprising the bioburden;
- c) environment in which the microorganisms occur;
- d) size of product;
- e) number of components;
- f) complexity of product;
- g) degree of automation during manufacture;
- h) manufacturing environment.

4.3.2 Master product

A member of a product family shall only be considered a master product if assessment (see 4.3.1.3) indicates that the member presents a challenge to the sterilization process that is greater than that of all other product family members. In some situations, there can be several products within the product family, each of which could be considered as the master product. In such circumstances, any one of these products may be selected as the master product to represent the family, either

- a) at random, or
- b) according to a documented procedure to include the different products, each of which could be considered as the master product.

4.3.3 Equivalent product

A group of product shall only be considered equivalent if assessment (see 4.3.1.3) indicates that group members require the same sterilization dose. Selection of the equivalent product to represent the family shall be either a) at random, or b) according to a documented procedure to include different members of the product family. The manufacturing volume and availability of product should be considered in the selection of the equivalent product to represent the product family.

4.3.4 Simulated product

A simulated product shall only represent a product family if it constitutes an equivalent or greater challenge to the sterilization process than that provided by members of the product family. Simulated product shall be packaged in a manner and with materials used for the actual product.

NOTE A simulated product is not intended for clinical use; it is fabricated solely for the establishment or maintenance of the sterilization dose.

A simulated product may be:

- a) one that is similar to the actual product in terms of materials and size, and subjected to similar manufacturing processes; e.g., a piece of the material, used for implants, that goes through the entire manufacturing process; or
- b) a combination of components from product within the product family that would not typically be combined for use; e.g., a tubing set containing multiple filters, clamps, and stopcocks that are components of other products within the product family.

4.4 Maintaining product families

4.4.1 Periodic review

Review shall be performed at a specified frequency to ensure that product families and product used to represent each product family remain valid. Responsibility for reviews of product and/or processes that might affect membership of product families shall be allocated to competent personnel. Such review shall be performed at least annually. The outcome of the review shall be recorded in accordance with 4.1.2 of ISO 11137-1:2006.

4.4.2 Modification to product and/or manufacturing process

Modifications to product, such as raw materials (nature and source), components or product design (including size), and/or modifications to the manufacturing process, such as equipment, environment, or location, shall be assessed through a formal, documented change control system. Such modifications can alter the basis on which the product family was defined or the basis on which the selection of product to represent the product family was made. Significant changes can require definition of a new product family or the selection of a different representative product.

4.4.3 Records

Records of product families shall be retained (see 4.1.2 of ISO 11137-1:2006).

4.5 Consequence of failure of sterilization dose substantiation or sterilization dose audit

In the event of failure during substantiation of a selected sterilization dose or performance of the sterilization dose audit for a product family, all members of that family shall be considered to be affected. Subsequent actions shall apply to all members comprising the product family.

5 Selection and testing of product for substantiating and auditing a selected sterilization dose

5.1 Nature of product

5.1.1 Product for sterilization can consist of:

- a) an individual health care product in its packaging system;
- b) a set of components presented in a packaging system, which are assembled at the point of use to form the health care product, together with accessories required to use the assembled product;
- c) a number of identical health care products in their packaging system;
- d) a kit comprising a variety of procedure-related health care products.

Product items for sterilization dose substantiation and for sterilization dose auditing shall be taken in accordance with Table 1.

Table 1 — Nature of product items for sterilization dose substantiation and for sterilization dose auditing

Product type	Item for bioburden determination and verification dose experiment	Rationale
Individual health care product in its packaging system	Individual health care product	Each health care product is used independently in clinical practice.
Set of components in a packaging system	Combination of all components of the product	Components are assembled as a product and used together in clinical practice.
Number of identical health care products in their packaging system	Single health care product taken from the packaging system	Each health care product is used independently in clinical practice; the SAL of an individual health care product within the packaging system meets the selected SAL, although the overall SAL associated with the packaging system might be higher.
Kit of procedure-related health care products ^a	Each type of health care product comprising the kit	Each health care product is used independently in clinical practice.
^a In dose establishment, the sterilization dose is chosen based on the health care product requiring the highest sterilization dose.		

5.1.2 If the product has a claim of sterility for part of the product, the sterilization dose may be established on the basis of that part only.

EXAMPLE If the product has a label claim of sterility for the fluid path only, the sterilization dose may be established based on bioburden determinations and outcomes of tests of sterility performed on the fluid path.